Datong’s products will equip Elsevier to foray into the emerging clinical decision support (CDS) market in China, thereby helping Chinese hospitals to improve their quality of care through better drug usage and reduced prescription errors.
Elsevier, on its part, will integrate its global advanced CDS content and technology with Datong’s locally-tailored products and services which will help Chinese hospitals and pharmacies achieve reform objectives.
Datong’s flagship product ‘Clinical Drug Consultation and Safety Monitoring System’ provides drug based alerts and warnings at order entry as well as drug reference information.
Additionally, its new products, namely ‘Utilization Analysis and Controls System for Anti-Bacteria Agents’ and ‘Prescription Review and Evaluation Program,’ are unique tools which aid hospitals in complying with new drug usage safety regulations.
Elsevier Health Sciences MD for Greater China and Korea Victor Lam said both companies would endeavor to provide better products and services to hospitals, users and health information system partners in the future.